Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
Times cited: 7
- Eculizumab treatment of atypical haemolytic uraemic syndrome: Results from the largest prospective clinical trial to date. Critical care (London, England). 2014 Information Resource GET IT
- Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. The New England journal of medicine. 2013 Academic Article GET IT